logo
Plus   Neg
Share
Email

Biotech IPOs For The Week Ahead

ipo-aug13-lt.jpg

In the healthcare sector, 5 companies have made their stock market debut this month.

Now, let's take a look at the U.S. biotech IPO calendar of the week ahead.

1. ALZHEON INC.

Alzheon is a U.S. clinical-stage biopharmaceutical company developing medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders.

The company is scheduled to list its IPO on the Nasdaq Global Select Market, under the symbol "ALZH", on October 24.

Alzheon has offered to sell 2.5 million shares of its common stock in the offering, and the underwriters have an option for 30 days to purchase up to 375 thousand additional shares of common stock.

The initial public offering price is expected to be between $13 and $15 per share.

Underwriters of the IPO:

ThinkEquity, a division of Fordham Financial Management, Inc., H.C. Wainwright & Co., LLC and The Benchmark Company, LLC.

Pipeline:

The Company's lead product candidate is ALZ-801, under phase Ib clinical trial in the United States in Alzheimer's disease patients who possess one or two copies of the APOE4 gene.

Also in the pipeline is preclinical candidate ALZ-1903, a potent inhibitor of beta amyloid misfolding.

Near-term Catalyst:

- Initiate a phase IIb trial for ALZ-801 in APOE4/4 homozygous patients with early to mild Alzheimer's disease in the first half of 2019.

2. Gamida Cell Ltd.

Gamida Cell is a clinical-stage biopharmaceutical company developing novel cell therapies for difficult-to-treat cancers and rare, serious hematologic diseases.

The company is scheduled to list its IPO on the Nasdaq Global Select Market, under the symbol "GMDA", on October 26.

Gamida Cell has offered to sell 3.57 million shares of its common stock in the offering, and the underwriters have an option for 30 days to purchase up to 536 thousand additional shares of common stock.

The initial public offering price is expected to be between $13 and $15 per share.

Underwriters of the IPO:

BMO Capital Markets Corp. and RBC Capital Markets, LLC, Needham & Company, LLC and Oppenheimer & Co. Inc.

Pipeline:

Gamida Cell's lead product candidate is NiCord, a Phase III NAM-expanded cord blood cell therapy in patients with number of hematologic malignancies. NiCord is also being explored for bone marrow failure disorders, and is being evaluated in a Phase I/II trial in patients with severe aplastic anemia.

Also in the pipeline is NAM-NK to address current limitations in NK-based cell therapies and is currently in an investigator-sponsored Phase 1 trial in combination with antibodies in adult patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma.

Near-term Catalyst:

- Top-line data from Phase III trial of NiCord is anticipated in the first half of 2020.
- Preliminary data from Phase I/II trial of NiCord is expected in 2019.
- Preliminary data from Phase 1 trial of NAM-NK in combination with antibodies is expected by the end of 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT